FIELD: medicine; pharmacology.
SUBSTANCE: group of inventions relates to the field of medicine and pharmacology, namely to the treatment of motor disorders such as Tourette’s syndrome. More specifically, the use of (+)-α-dihydrotetrabenazine or its pharmaceutically acceptable salt for the treatment of a hyperkinetic motor disorder is described, where treatment includes determination of an approximate mass of a subject, and: (i) when the subject has a mass of 30-50 kg, the injection of maximum daily amount of (+)-α-dihydrotetrabenazine or its pharmaceutically acceptable salt corresponding to from 2 mg to 7.5 mg of a free base of (+)-α-dihydrotetrabenazine; (ii) when the subject has a mass of 50-75 kg, the injection of maximum daily amount of (+)-α-dihydrotetrabenazine or its pharmaceutically acceptable salt corresponding to from 5 mg to 10 mg of a free base of (+)-α-dihydrotetrabenazine; (iii) when the subject has a mass of 75-95 kg, the injection of maximum daily amount of (+)-α-dihydrotetrabenazine or its pharmaceutically acceptable salt corresponding to from 7.5 mg to 15 mg of a free base of (+)-α-dihydrotetrabenazine; or (iv) when the subject has a mass of more than 95 kg, the injection of maximum daily amount of (+)-α-dihydrotetrabenazine or its pharmaceutically acceptable salt corresponding to from 15 mg to 20 mg of a free base of (+)-α-dihydrotetrabenazine; the amount of (+)-α -dihydrotetrabenazine injected per day is from 15 mg to 20 mg. In addition, a method for the treatment of hyperkinetic motor disorder is described, using the above-described scheme of injection of (+)-α-dihydrotetrabenazine.
EFFECT: providing effective treatment of hyperkinetic motor disorder.
18 cl, 10 dwg, 2 tbl, 4 ex
